Business Context and Reporting Period
This Form 8-K Current Report was filed by Teva Pharmaceutical Industries Ltd. on November 5, 2024. The filing reports a corporate governance event: the election of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Mr. Chen Lichtenstein to the Board of Directors, effective December 1, 2024, serving until the 2025 annual meeting of shareholders. The Board determined that Mr. Lichtenstein qualifies as an independent director under New York Stock Exchange listing rules.
Management Commentary and Background
- Professional Background: Mr. Lichtenstein previously served as CFO of Syngenta Group Ltd. (2020–2023) and President/CEO of ADAMA Ltd. (2014–2020). He also held executive roles at ChemChina and Goldman Sachs.
- Education: He holds a Ph.D. in Business Administration and a J.S.D. from Stanford University, as well as degrees from the Hebrew University of Jerusalem.
- Compensation: He will receive the same compensation as other non-executive directors, as detailed in the Company's definitive proxy statement filed on April 16, 2024.
- Independence: There are no arrangements or understandings regarding his election, no material interest in related party transactions, and no family relationships with existing directors or officers.
Investor Verification Checklist
- Verify the effective date of Mr. Lichtenstein's board membership (December 1, 2024).
- Review the definitive proxy statement filed on April 16, 2024, for specific director compensation details.
- Confirm the independence status of the new director per NYSE listing rules.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.